Regeneron’s Libtayo/Fianlimab LAGs Bristol’s Opdualag On Timing, But May Win On Efficacy
Company Looks At Coformulation
The PD-1/LAG-3 combination showed a high response rate in a small number of melanoma patients with prior PD-1 exposure.
You may also be interested in...
The company will pay $900m upfront to buy Sanofi's stake in the PD-1 inhibitor, which is a cornerstone of Regeneron's strategy to build an oncology portfolio.
The LAG-3 antibody relatlimab, with Opdivo in the fixed-dose combo Opdualag and a $27,389-per-dose price, is the first approved in a new class of checkpoint inhibitors since the anti-PD-1/PD-L1s.
Clinical data released on drugs targeting LAG-3 from BMS, Regeneron, Merck & Co. and Immutep in a variety of cancers.